r the Bioresearch Monitoring 
Program.'' One of the performance goals, referenced in a letter to 
Congress from the Secretary of Health and Human Services that 
accompanied the Medical Device User Fee and Modernization Act of 2002 
(MDUFMA) legislation, includes a commitment to improve FDA's scheduling 
and timeliness of preapproval inspections. This draft guidance document 
is intended to assist applicants in understanding the process involved 
in the bioresearch monitoring (BIMO) review of the clin